Professor Alex Rothman
MA, BM BCh, MRes, PhD, MRCP, EEGC
Clinical Medicine, School of Medicine and Population Health
Professor of Cardiology
Honorary Consultant Cardiologist
+44 114 215 9521
Full contact details
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Profile
-
For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk
I trained in medicine at Cambridge and Oxford and joined the University of Sheffield in 2008 as an Academic Clinical Fellow working as part of a team investigating the therapeutic tractability of inflammation in patients suffering heart attacks (the MRC ILA Heart study).
Through my MRC Clinical Research Training Fellowship I developed an interest in the pathology and treatment of cardiovascular diseases and have been closely involved in studies investigating new therapies and devices for the treatment of pulmonary arterial hypertension, atherosclerosis and heart failure.
I am currently a Wellcome Trust Career Development Fellow and an Honorary Consultant Cardiologist at Sheffield Teaching Hospitals NHS Trust.
- Research interests
-
My research interests are the pathology and treatment of cardiovascular and pulmonary vascular diseases.
The MRC ILA Heart study was the first randomised study to demonstrate the therapeutic tractability of inflammatory signalling in coronary artery disease. Findings were published in the European Heart Journal and the New England Journal of Medicine and validated by CANTOS, a phase III study of the interleukin-1 beta targeted therapy Canakinumab that demonstrated a reduction in recurrent cardiac events.
My current work focuses on the pathology of pulmonary arterial hypertension and the development of novel therapeutic strategies. Recent pre-clinical studies have led to early phase clinical studies of pulmonary artery denervation, implantable pulmonary artery pressure monitors and new drug studies.
Current projects:
- Wellcome Trust Clinical Research Career Development Fellowship: Determining Novel SMURF1 Signalling Pathways and Precision Medicine Strategies in Patients with Pulmonary Arterial Hypertension, £460,409.
- MRC Confidence in Concepts, The Feasibility of Novel Clinical Trial Infrastructure, Design and Technology for Early Phase Studies in Patients with Pulmonary Arterial Hypertension (FIT-PH), £65,610 (PI)
- British Heart Foundation, Development of a Prototype Pericardial Left Ventricular Assist Device, £249,967 (Co-I)
- Medtronic Inc. Non-invasive phenotyping of arrhythmias in pulmonary arterial hypertension, £200,000
- Association of Physicians of Great Britain and Ireland Young Investigator Award, £19,973
- Academy of Medical Sciences, Starter Grants for Clinical Lecturers: Inhibition of SMURF1 for the Treatment of Pulmonary Arterial Hypertension, £30,000
- EPSRC/HEFCE and Endotronix: Intra-arterial Pulmonary Artery Pressure Monitoring in Pulmonary Hypertension: Re-defining Clinical Measurement of Treatment Effect and Disease Progression, £84,711
- TROPHY: Therapeutic Intravascular Ultrasound for the treatment of pulmonary arterial hypertension (https://clinicaltrials.gov/ct2/show/NCT02516722)
- SIRONA: A Prospective, Multi-Center, Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella Heart Failure System in NYHA Class III Heart Failure Patients. (https://clinicaltrials.gov/ct2/show/NCT03375710)
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Intravascular ultrasound pulmonary artery denervation to treat pulmonary arterial hypertension (TROPHY1): multicenter, early feasibility study. JACC: Cardiovascular Interventions, 13(8), 989-999. View this article in WRRO
- IL-6 in pulmonary hypertension: why novel is not always best. European Respiratory Journal, 55(4), 2000314-2000314.
- Identification of cardiac MRI thresholds for risk stratification in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 201(4), 458-468. View this article in WRRO
- Effects of interleukin-1β Inhibition on blood pressure, incident hypertension, and residual inflammatory risk. Hypertension, 75(2), 477-482. View this article in WRRO
- A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. Nature Communications, 10(1). View this article in WRRO
- Arrhythmic burden and outcomes in pulmonary arterial hypertension. Frontiers in Medicine, 6. View this article in WRRO
- Pulmonary artery denervation using catheter based ultrasonic energy.. EuroIntervention. View this article in WRRO
- Express: The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry.. Pulmonary Circulation. View this article in WRRO
- The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 52(3). View this article in WRRO
- Interleukin-1 beta inhibition with canakinumab and reducing lung cancer—subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS). Journal of Thoracic Disease, 10(S26), S3084-S3087.
- Dietary Docosahexaenoic Acid Reduces Oscillatory Wall Shear Stress, Atherosclerosis, and Hypertension, Most Likely Mediated via an IL‐1–Mediated Mechanism. Journal of the American Heart Association, 7(13). View this article in WRRO
- Canakinumab for Atherosclerotic Disease. The New England journal of medicine, 378(2), 196-200. View this article in WRRO
- The Canakinumab Antiinflammatory Thrombosis Outcome Study Trial—The Starting Gun Has Fired. Journal of Thoracic Disease, 9, 4922-4925. View this article in WRRO
- Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 196(2). View this article in WRRO
- Incremental Shuttle Walking Test Distance and Autonomic Dysfunction Predict Survival in Pulmonary Arterial Hypertension. The Journal of Heart and Lung Transplantation. View this article in WRRO
- miRNA-140-5p: new avenue for pulmonary arterial hypertension drug development?. Epigenomics. View this article in WRRO
- MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension. Journal of Clinical Investigation, 126(7), 2495-2508. View this article in WRRO
- Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline. JACC: Cardiovascular Interventions, 8(15), 2013-2023.
- Pulmonary Artery Denervation Reduces Pulmonary Artery Pressure and Induces Histological Changes in an Acute Porcine Model of Pulmonary Hypertension. Circulation: Cardiovascular Interventions, 8(11), e002569-e002569. View this article in WRRO
- Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes. Circulation: Cardiovascular Interventions, 8(11). View this article in WRRO
- MicroRNA in pulmonary vascular disease.. Prog Mol Biol Transl Sci, 124, 43-63.
- View this article in WRRO The Effect of Interleukin-1 Receptor Antagonist Therapy on Markers of Inflammation in Non-ST Elevation Acute Coronary Syndromes: The MRC-ILA Heart Study. CIRCULATION, 128(22).
- Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling.. Cardiovasc Res, 100(2), 252-261. View this article in WRRO
- Intracellular retention of mutant retinoschisin is the pathological mechanism underlying X-linked retinoschisis. Human molecular genetics, 11(24), 3097-3105.
- Digital health care solution for proactive heart failure management with the Cordella Heart Failure System : results of the SIRONA first‐in‐human study. European Journal of Heart Failure. View this article in WRRO
- klf2ash317 Mutant Zebrafish Do Not Recapitulate Morpholino-Induced Vascular and Haematopoietic Phenotypes. PLoS ONE, 10(10). View this article in WRRO
All publications
Journal articles
- The spectrum of systemic sclerosis-associated pulmonary hypertension: Insights from the ASPIRE registry. The Journal of Heart and Lung Transplantation, 43(10), 1629-1639. View this article in WRRO
- Association of risk assessment at diagnosis with healthcare resource utilization and health‐related quality of life outcomes in pulmonary arterial hypertension. Pulmonary Circulation, 14(3). View this article in WRRO
- Modelled impact of virtual fractional flow reserve in patients undergoing coronary angiography (VIRTU-4). Heart. View this article in WRRO
- Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public representatives. BMJ Open, 14(3). View this article in WRRO
- Pulmonary hypertension: intensification and personalization of combination Rx (PHoenix): a phase IV randomized trial for the evaluation of dose‐response and clinical efficacy of riociguat and selexipag using implanted technologies. Pulmonary Circulation, 14(1). View this article in WRRO
- Systematic pulmonary embolism follow-up increases diagnostic rates of chronic thromboembolic pulmonary hypertension and identifies less severe disease: results from the ASPIRE Registry. European Respiratory Journal, 63(3). View this article in WRRO
- Radiation to Illuminate the Path of Neuromodulation for Pulmonary Hypertension. JACC: Basic to Translational Science, 9(2), 257-259.
- Improving Prognostication in Pulmonary Hypertension Using AI-quantified Fibrosis and Radiologic Severity Scoring at Baseline CT. Radiology, 310(2).
- Risk assessment and real-world outcomes in chronic thromboembolic pulmonary hypertension: insights from a UK pulmonary hypertension referral service. BMJ Open, 14(1). View this article in WRRO
- The left atrial area derived cardiovascular magnetic resonance left ventricular filling pressure equation shows superiority over integrated echocardiography. Medicina, 59(11). View this article in WRRO
- The Left Atrial Area Derived Cardiovascular Magnetic Resonance Left Ventricular Filling Pressure Equation Shows Superiority over Integrated Echocardiography. Medicina (Kaunas, Lithuania), 59(11).
- Establishing minimally important differences for cardiac MRI end-points in pulmonary arterial hypertension. European Respiratory Journal, 62(2), 2202225-2202225.
- Wearable technology and the cardiovascular system: the future of patient assessment. The Lancet Digital Health, 5(7), e467-e476.
- Non-invasive detection of severe PH in lung disease using magnetic resonance imaging. Frontiers in Cardiovascular Medicine, 10.
- A Subcutaneous Multiparameter Sensor With Integrated Interstitial Fluid Pressure Measurement for Remote Heart Failure Monitoring. JACC: Basic to Translational Science, 8(4), 386-388.
- Oral Presentation No. 84 Initial clinical experience with 6-hour enoxaparin regimen in opiate-treated patients undergoing primary percutaneous coronary intervention. Cardiovascular Research, 118(Supplement_2).
- Validation of Artificial Intelligence Cardiac MRI Measurements: Relationship to Heart Catheterization and Mortality Prediction. Radiology, 304(3), E56-E56.
- Atrial flutter and fibrillation in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension in the ASPIRE registry: Comparison of rate versus rhythm control approaches. International Journal of Cardiology.
- Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response.. Heart.
- Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications.. Eur Heart J.
- Machine learning cardiac-MRI features predict mortality in newly diagnosed pulmonary arterial hypertension. European Heart Journal - Digital Health. View this article in WRRO
- Training and clinical testing of artificial intelligence derived right atrial cardiovascular magnetic resonance measurements. Journal of Cardiovascular Magnetic Resonance, 24(1).
- Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 12. View this article in WRRO
- Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy. Pulmonary Circulation, 11(4). View this article in WRRO
- Design of a randomised, double-blind, crossover, placebo-controlled trial of effects of sildenafil on cerebrovascular function in small vessel disease: Oxford haemodynamic adaptation to reduce pulsatility trial (OxHARP). European Stroke Journal, 6(3), 283-290. View this article in WRRO
- A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. EBioMedicine, 69, 103444-103444.
- Design of a randomised, double-blind, crossover, placebo-controlled trial of effects of sildenafil on cerebrovascular function in small vessel disease: Oxford haemodynamic adaptation to reduce pulsatility trial (OxHARP). European stroke journal, 6(3), 283-290.
- The Impact of Virtual Fractional Flow Reserve and Virtual Coronary Intervention Upon Treatment Decisions in the Cardiac Catheter Laboratory. Canadian Journal of Cardiology.
- Cardiovascular magnetic resonance predicts all-cause mortality in pulmonary hypertension associated with heart failure with preserved ejection fraction.. Int J Cardiovasc Imaging.
- Preclinical testing of a novel pericardial left ventricular assist device (PALVAD). European Heart Journal Acute Cardiovascular Care, 10(Supplement_1), zuab020.035.
- Preclinical testing of a novel pericardial left ventricular assist device (PALVAD). European Heart Journal. Acute Cardiovascular Care, 10(Suppl 1).
- Standard and emerging CMR methods for mitral regurgitation quantification. International Journal of Cardiology.
- Meta‐analysis of echocardiographic quantification of left ventricular filling pressure. ESC Heart Failure. View this article in WRRO
- Right Ventricular Adaptation Assessed Using Cardiac Magnetic Resonance Predicts Survival in Pulmonary Arterial Hypertension. JACC: Cardiovascular Imaging.
- Pericardial Left Ventricular Assist Device (PALVAD) development via large animal and cadaveric models. European Heart Journal, 41(Supplement_2).
- Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension. Pulmonary Circulation, 10(4).
- TCT CONNECT-180 Novel Pericardial Left Ventricular Assist Device (PALVAD) Assessment via Large Animal and Cadaveric Models. Journal of the American College of Cardiology, 76(17), B77-B77.
- Emerging therapies for right ventricular dysfunction and failure. Cardiovascular Diagnosis and Therapy, 10(5), 1735-1767.
- Validation of four-dimensional flow cardiovascular magnetic resonance for aortic stenosis assessment. Scientific Reports, 10(1). View this article in WRRO
- Age-associated changes in 4D flow CMR derived tricuspid valvular flow and right ventricular blood flow kinetic energy. Scientific Reports, 10(1). View this article in WRRO
- Intravascular ultrasound pulmonary artery denervation to treat pulmonary arterial hypertension (TROPHY1): multicenter, early feasibility study. JACC: Cardiovascular Interventions, 13(8), 989-999. View this article in WRRO
- IL-6 in pulmonary hypertension: why novel is not always best. European Respiratory Journal, 55(4), 2000314-2000314.
- Identification of cardiac MRI thresholds for risk stratification in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, 201(4), 458-468. View this article in WRRO
- Effects of interleukin-1β Inhibition on blood pressure, incident hypertension, and residual inflammatory risk. Hypertension, 75(2), 477-482. View this article in WRRO
- Rationale and design of the CardioMEMS Post‐Market Multinational Clinical Study: COAST. ESC Heart Failure, 7(3), 865-872.
- A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. Nature Communications, 10(1). View this article in WRRO
- The double-kissing nano-crush for bifurcation lesions : development, bioengineering, fluid dynamics and initial clinical testing. Canadian Journal of Cardiology. View this article in WRRO
- A systematic review of 4D-flow MRI derived mitral regurgitation quantification methods. Frontiers in Cardiovascular Medicine, 6. View this article in WRRO
- Arrhythmic burden and outcomes in pulmonary arterial hypertension. Frontiers in Medicine, 6. View this article in WRRO
- Pulmonary artery denervation using catheter based ultrasonic energy.. EuroIntervention. View this article in WRRO
- Express: The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry.. Pulmonary Circulation. View this article in WRRO
- Commentary on: evaluation of a newly developed 2D parametric parenchymal blood flow technique with an automated vessel suppression algorithm in patients with chronic thromboembolic pulmonary hypertension undergoing balloon pulmonary angioplasty. Clinical Radiology, 74(6), 435-436.
- A Systematic Review of Right Ventricular Diastolic Assessment by 4D Flow CMR. BioMed Research International, 2019. View this article in WRRO
- The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 52(3). View this article in WRRO
- Interleukin-1 beta inhibition with canakinumab and reducing lung cancer—subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS). Journal of Thoracic Disease, 10(S26), S3084-S3087.
- Dietary Docosahexaenoic Acid Reduces Oscillatory Wall Shear Stress, Atherosclerosis, and Hypertension, Most Likely Mediated via an IL‐1–Mediated Mechanism. Journal of the American Heart Association, 7(13). View this article in WRRO
- Canakinumab for Atherosclerotic Disease. The New England journal of medicine, 378(2), 196-200. View this article in WRRO
- From Theory-Inspired to Theory-Based Interventions: A Protocol for Developing and Testing a Methodology for Linking Behaviour Change Techniques to Theoretical Mechanisms of Action. Annals of Behavioral Medicine, 52(6), 501-512.
- The Canakinumab Antiinflammatory Thrombosis Outcome Study Trial—The Starting Gun Has Fired. Journal of Thoracic Disease, 9, 4922-4925. View this article in WRRO
- Prognostic Significance of Reduced Blood Pressure Response to Exercise in Pediatric Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 196(11). View this article in WRRO
- Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling. Pulmonary Circulation. View this article in WRRO
- Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 196(2). View this article in WRRO
- Incremental Shuttle Walking Test Distance and Autonomic Dysfunction Predict Survival in Pulmonary Arterial Hypertension. The Journal of Heart and Lung Transplantation. View this article in WRRO
- Endothelial repair in stented arteries is accelerated by inhibition of Rho-associated protein kinase. Cardiovascular Research, 112(3), 689-701. View this article in WRRO
- miRNA-140-5p: new avenue for pulmonary arterial hypertension drug development?. Epigenomics. View this article in WRRO
- MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension. Journal of Clinical Investigation, 126(7), 2495-2508. View this article in WRRO
- Response to Letter Regarding Article, “Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Study”. Circulation: Cardiovascular Interventions, 9(1).
- Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline. JACC: Cardiovascular Interventions, 8(15), 2013-2023.
- Pulmonary Artery Denervation Reduces Pulmonary Artery Pressure and Induces Histological Changes in an Acute Porcine Model of Pulmonary Hypertension. Circulation: Cardiovascular Interventions, 8(11), e002569-e002569. View this article in WRRO
- Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes. Circulation: Cardiovascular Interventions, 8(11). View this article in WRRO
- Audit of cardiac catheterisation in a DGH: implications for training and patient safety. British Journal of Cardiology, 21, 118-119.
- MicroRNA in pulmonary vascular disease.. Prog Mol Biol Transl Sci, 124, 43-63.
- View this article in WRRO The Effect of Interleukin-1 Receptor Antagonist Therapy on Markers of Inflammation in Non-ST Elevation Acute Coronary Syndromes: The MRC-ILA Heart Study. CIRCULATION, 128(22).
- Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling.. Cardiovasc Res, 100(2), 252-261. View this article in WRRO
- Reflective and Automatic Processes in the Initiation and Maintenance of Dietary Change. Annals of Behavioral Medicine, 38(S1), 4-17.
- Intracellular retention of mutant retinoschisin is the pathological mechanism underlying X-linked retinoschisis. Human molecular genetics, 11(24), 3097-3105.
- Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation. Expert Review of Cardiovascular Therapy, 1-7.
- Cerebrovascular Effects of Sildenafil in Small Vessel Disease: The OxHARP Trial. Circulation Research.
- Furthering Scientific Inquiry for Weight Loss Maintenance: Assessing the Psychological Processes Impacted by a Low intensity Technology-Assisted Intervention (NULevel Trial). Annals of Behavioral Medicine.
- Anatomical characterization of pulmonary artery and implications to pulmonary artery pressure monitor implantation. Scientific Reports, 13(1).
- Technical Assistance Received by Older Adults to Use Commercially Available Physical Activity Monitors: An Ad-hoc Study of the Ready Steady 3.0 Trial (Preprint). JMIR mHealth and uHealth.
- Rethinking how and when to report descriptions of behavior change content within interventions: a case study of an ongoing physical activity trial (ready steady 3.0). Translational Behavioral Medicine.
- Ambulatory haemodynamic‐guided management reduces heart failure hospitalizations in a multicentre European heart failure cohort. ESC Heart Failure.
- Quantitative CT Evaluation of Small Pulmonary Vessels Has Functional and Prognostic Value in Pulmonary Hypertension. Radiology.
- Validation of Artificial Intelligence Cardiac MRI Measurements: Relationship to Heart Catheterization and Mortality Prediction. Radiology.
- Severe pulmonary hypertension associated with lung disease is characterised by a loss of small pulmonary vessels on quantitative CT. ERJ Open Research, 00503-2021.
- Imaging and Risk Stratification in Pulmonary Arterial Hypertension: Time to Include Right Ventricular Assessment. Frontiers in Cardiovascular Medicine, 9.
- Investigating Microtemporal Processes Underlying Health Behavior Adoption and Maintenance: Protocol for an Intensive Longitudinal Observational Study (Preprint). JMIR Research Protocols.
- Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study. Thorax.
- A Current and Future Outlook on Upcoming Technologies in the Remote Monitoring of Patients with Heart Failure. European Journal of Heart Failure.
- Maximal Exercise Testing Using the Incremental Shuttle Walking Test Can Be Used to Risk Stratify Patients with Pulmonary Arterial Hypertension. Annals of the American Thoracic Society.
- Balloon Pulmonary Angioplasty: State of the Art. Interventional Cardiology Review, 16.
- Clinical predictors of all‐cause mortality in patients presenting to specialist heart failure clinic with raised NT‐proBNP and no heart failure. ESC Heart Failure. View this article in WRRO
- Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention. Platelets. View this article in WRRO
- Digital health care solution for proactive heart failure management with the Cordella Heart Failure System : results of the SIRONA first‐in‐human study. European Journal of Heart Failure. View this article in WRRO
- Diagnostic accuracy of CT pulmonary angiography in suspected pulmonary hypertension. European Radiology. View this article in WRRO
- mir-140-5p and SMURF1 regulate pulmonary arterial hypertension. Journal of Clinical Investigation.
- klf2ash317 Mutant Zebrafish Do Not Recapitulate Morpholino-Induced Vascular and Haematopoietic Phenotypes. PLoS ONE, 10(10). View this article in WRRO
- View this article in WRRO Left ventricular blood flow kinetic energy is associated with the six-minute walk test and LV remodelling post valvular intervention in aortic stenosis.. Quantitative imaging in medicine and surgery.
- Feasibility and safety of a telemetric pulmonary artery pressure monitoring system in acute and chronic porcine models of pulmonary hypertension.
Conference proceedings papers
- S38 Incidence and phenotypic predictors of arrhythmias in idiopathic pulmonary arterial hypertension. ‘Right here, right now’ – Bench to bedside in pulmonary vascular disease
- Systematic Follow-up of Patients Following Acute Pulmonary Embolism Identifies High Incidence of Chronic Thromboembolic Pulmonary Hypertension: ASPIRE CTEPH. D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE
- Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH (REPEAT-PAH). B57. INTERMEDIATES, CORRELATES, AND SURROGATES, OH MY!: NOVEL END POINTS AND ASSESSMENTS IN PVD
- 33 Cardiac MRI thresholds for improvement in pulmonary arterial hypertension. Abstracts
- New diagnostic criteria and PVR thresholds in SSc-associated PH: Insights from the ASPIRE registry. 13.01 - Pulmonary hypertension
- Correlation of emPHasis-10 with clinical tests: insights from the ASPIRE registry. 13.01 - Pulmonary hypertension
- The effect of parenchymal lung disease on patient characteristics and outcome in SSc-PH: Insights from the ASPIRE registry. 13.01 - Pulmonary hypertension
- S93 Systematic follow-up of patients following acute pulmonary embolism is associated with an increased incidence of chronic thromboembolic pulmonary hypertension and less severe disease. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
- S92 Remote monitoring enabled evaluation of risk and physiological response to therapeutic escalation and clinical worsening in patients with pulmonary hypertension. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
- S90 Right ventricular remodelling assessed using cardiac magnetic resonance predicts survival and treatment response in pulmonary arterial hypertension. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
- P81 Effect of COVID-19 infection and preventive public health measures on haemodynamics, activity and quality of life in patients with pulmonary arterial hypertension. ‘Contagion’ – The impact of COVID-19
- P38 Assessing the repeatability of NT-proBNP testing using laboratory and point of care testing in PAH (REPEAT-PAH). ‘Mission (Im)possible I’ – Pulmonary vascular disease
- S91 Remote monitored physical activity is related to established measures of clinical risk in patients with pulmonary arterial hypertension. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
- P37 Correlation of emPHasis-10 with clinical tests: insights from the ASPIRE registry. ‘Mission (Im)possible I’ – Pulmonary vascular disease
- Abstract 13553: Remote Monitoring of the Haemodynamic Response to Clinically Indicated Therapeutic Escalation and Clinical Worsening Events in Patients With Pulmonary Arterial Hypertension. Circulation, Vol. 146(Suppl_1) (pp a13553-a13553)
- Abstract 13527: The Development of a Remote Pulmonary Arterial Hypertension Risk Score Utilising Remote Monitoring Technology to Monitor Parameters Associated With Mortality in Pulmonary Arterial Hypertension. Circulation, Vol. 146(Suppl_1) (pp a13527-a13527)
- Training and Clinical Validation of Artificial Intelligence Derived Right Atrial Cardiovascular Magnetic Resonance Measurements. A105. YOU CAN PREDICT ALL YOU WANT, BUT EVERYONE KNOWS...
- Abstract 13581: Heart Rhythm versus Heart Rate Control Strategy in Patients With Pre-Capillary Pulmonary Hypertension and Atrial Arrhythmias. Circulation, Vol. 144(Suppl_1)
- 19 Cardiac magnetic resonance to identify raised left ventricular filling pressure. Abstracts
- 124 Comparing the safety and feasibility of implanting pulmonary artery pressure monitors via the internal jugular vein compared to standard femoral venous access in patients with pulmonary arterial hypertension. Heart failure
- 121 Effect of UK COVID-19 public health measures on activity and quality of life in patients with pulmonary arterial hypertension. Heart failure
- Heart Rhythm versus Heart Rate Control Strategy in Patients With Pre-Capillary Pulmonary Hypertension and Atrial Arrhythmias. CIRCULATION, Vol. 144
- Abstract 15636: Effect of COVID-19 Public Health Measures on Activity and Quality of Life in Patients With Pulmonary Arterial Hypertension. Circulation, Vol. 142(Suppl_3) View this article in WRRO
- Percent-predicted incremental shuttle walking test distance stratifies risk in pulmonary arterial hypertension. Pulmonary hypertension
- Serial cardiac MRI for assessment of cardiac morphology and function in CTEPH patients after PEA or vasodilator therapy. Pulmonary hypertension
- Percutaneous Endovascular Ultrasound Pulmonary Artery Denervation for the Treatment of Pulmonary Arterial Hypertension: 12-Month Results of the Trophy 1 Study. D63. PULMONARY EMBOLISM: CASE REPORTS AND LATE BREAKING
- A prospective study comparing the repeatability and sensitivity to change of non-invasive endpoints in pulmonary arterial hypertension: the RESPIRE study. Pulmonary hypertension
- 284An accurate, multi-parametric cardiovascular magnetic resonance model to predict mean pulmonary artery pressure in pulmonary hypertension. European Heart Journal - Cardiovascular Imaging, Vol. 20(Supplement_2)
- P612Averaged, diastolic mitral inflow velocity mapping versus peak velocity for the assessment of left ventricular haemodynamics. European Heart Journal - Cardiovascular Imaging, Vol. 20(Supplement_2) View this article in WRRO
- P165A novel cardiac magnetic resonance imaging model to predict level of mixed venous oxygen levels in pulmonary hypertension. European Heart Journal - Cardiovascular Imaging, Vol. 20(Supplement_2) View this article in WRRO
- The Incremental Shuttle Walking Test Can Be Used to Risk Stratify Patients with Pulmonary Hypertension as Per the European Respiratory/Cardiac Society Guidelines. A105. GLORY DAYS: THE LATEST CLINICAL RESEARCH IN PAH
- A novel cardiac magnetic resonance imaging model to predict level of mixed venous oxygen levels in pulmonary hypertension. EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, Vol. 20 (pp 121-121)
- S43 Circulatory levels of microrna-34a expression identify patients with poor clinical outcome, and regulate pulmonary vascular cell phenotype. Fundamental mechanisms of pulmonary arterial hypertension
- Expression of SMURF1 is Increased in Patients With Pulmonary Arterial Hypertension and SiRNA Inhibition of SMURF1 Reduces Pulmonary Artery Smooth Muscle Cell Proliferation. CIRCULATION, Vol. 138
- P612Feasibility and safety of a wireless pulmonary artery pressure monitoring system in chronic porcine models of pulmonary hypertension. European Heart Journal, Vol. 38(suppl_1) View this article in WRRO
- P245 Whole blood levels of microrna-34a predict survival and regulate genes associated with pulmonary arterial hypertension. Thorax, Vol. 71(Suppl 3) (pp A220.2-A221)
- Age is independently associated with pulmonary arterial compliance in health and in patients with pulmonary vascular disease. 4.3 Pulmonary Circulation and Pulmonary Vascular Diseases
- Age is independently associated with pulmonary arterial compliance in health and in patients with pulmonary vascular disease. EUROPEAN RESPIRATORY JOURNAL, Vol. 48
- E microRNA-140-5p and SMURF1 Regulate Pulmonary Arterial Hypertension. Heart, Vol. 102(Suppl 6) (pp A147-A147)
- S3 Reduced BMPR2 expression potentiates a pulmonary artery smooth muscle cell specific IL-1ß response. Thorax, Vol. 70(Suppl 3) (pp A5.3-A6)
- T5 MicroRNA-140–5p Regulates Disease Phenotype in Experimental Pulmonary Arterial Hypertension via SMURF1. Thorax, Vol. 70(Suppl 3) (pp A3.1-A3)
- T5 Opg Regulates Pulmonary Arterial Smooth Muscle Cell Proliferation And The Expression Of Pah-associated Genes Via Fas. Thorax, Vol. 69(Suppl 2) (pp A2-A3)
- 183 Novel OPG Protein Interactions Regulate Survival, Proliferation And Pah-associated Gene Expression in Pulmonary Arterial Smooth Muscle Cells. Heart, Vol. 100(Suppl 3) (pp A102.3-A103), 2 June 2014 - 4 June 2014.
- Novel OPG Protein Interactions Regulate Survival, Proliferation and PAH-Associated Gene Expression in Pulmonary Arterial Smooth Muscle Cells.. Heart, Vol. 100(Suppl 3:A102-3.)
- Bone Marrow Derived Osteoprotegerin Drives Experimental Pulmonary Arterial Hypertension In The Murine Sugen/hypoxia Model. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 189
- Novel Osteoprotegerin Protein Interactions Regulate Pulmonary Arterial Smooth Muscle Cell Survival And Proliferation. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 189
- Radio-Frequency Denervation Of The Pulmonary Artery Reduces Pulmonary Hypertension In An Acute Porcine Model. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 189
- The Effect of Interleukin-1 Receptor Antagonist Therapy on Markers of Inflammation in Non-ST Elevation Acute Coronary Syndromes: The MRC-ILA Heart Study. Circulation, Vol. 128(A14792)
- The Effect of Interleukin-1 Receptor Antagonist Therapy on Markers of Inflammation in Non-ST Elevation Acute Coronary Syndromes: The MRC-ILA Heart Study. Circulation, Vol. 128(A14792)
- PERIPHERAL WHOLE BLOOD MICRORNA SIGNATURE DIFFERENTIATES BETWEEN MYOCARDIAL INFARCTION AND UNSTABLE ANGINA. HEART, Vol. 97(20) (pp 7-7)
- INVESTIGATION OF IL-1 INHIBITION IN PATIENTS PRESENTING WITH NON-ST ELEVATION MYOCARDIAL INFARCTION ACUTE CORONARY SYNDROMES (THE MRC ILA HEART STUDY). HEART, Vol. 97 (pp A13-A13)
- RS1 mutations causing X-linked Juvenile Retinoschisis lead to intracellular retention of mutant retinoschisin.. AMERICAN JOURNAL OF HUMAN GENETICS, Vol. 71(4) (pp 554-554)
- Intracellular retention of mutant retinoschisin is the pathological mechanism underlying X-linked retinoschisis.. JOURNAL OF MEDICAL GENETICS, Vol. 39 (pp S15-S15)
Website content
Preprints
- Health-related quality of life in pulmonary arterial hypertension trials: a review and conceptual map, Cold Spring Harbor Laboratory.
- Remote evaluation of risk and physiological response to therapeutic escalation and clinical worsening in patients with pulmonary hypertension, Cold Spring Harbor Laboratory.
- Older Adults' Use of Physical Activity Monitors in an 18-Month Trial: Descriptive Study of Technical Problems and Assistance (Preprint), JMIR Publications Inc..
- Pulmonary Artery Anatomical Characterization: Relevance to Pulmonary Artery Pressure Sensors, Research Square Platform LLC.
- Teaching interests
-
I enjoy lecturing clinical cardiology to both undergraduates and post-graduates and I teach clinical skills to medical students and doctors.